Real‐World Validation of the Clinical Distinctiveness of IDH‐Mutant Glioblastoma in the SEER Transition Era: A Population‐Based Study Integrating Machine Learning
Brain and Behavior · 2026
DOI: 10.1002/brb3.71641 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Brain and Behavior, 2026. Verfasst von Dewei Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. Hauptthemen laut MEDLINE: Glioblastoma, Machine Learning, Brain Neoplasms, Isocitrate Dehydrogenase. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bureau of Science and Technology Nanchong City, North Sichuan Medical College, Affiliated Hospital of North Sichuan Medical College.
Abstract (Originalsprache)
Introduction
The 2021 WHO classification reclassified “IDH‐mutant glioblastoma (GBM)” as “Astrocytoma, IDH‐mutant, grade 4.” This study aims to provide real‐world validation of this reclassification using the specific ICD‐O‐3 code (9445/3) from the Surveillance, Epidemiology, and End Results (SEER) “Transition Era” (2018–2022) and develop a machine learning (ML)‐based prognostic model.
Methods
Patients diagnosed with IDH‐mutant GBM (9445/3) and GBM NOS (9440/3) were identified. Propensity Score Matching (PSM) and Inverse Probability of Treatment Weighting (IPTW) were employed to minimize bias. A doubly robust Cox regression model was constructed to quantify survival benefits. Nine ML algorithms were integrated to develop a prognostic signature, which was interpreted using SHAP (Shapley Additive exPlanations) analysis.
Results
Of 13,443 patients, 312 were IDH‐mutant. After matching, the IDH‐mutant group exhibited significantly superior overall survival (OS) and cancer‐specific survival (CSS) ( p < 0.001). IDH mutation emerged as a potent independent favorable prognostic factor, associated with a 65.0% lower mortality risk (HR = 0.350, p < 0.001). Subgroup analysis confirmed robust benefits from chemotherapy. The Random Forest (RF) model achieved the best performance (Test AUC = 0.698). SHAP analysis identified IDH status, chemotherapy, and age as the top predictors.
Conclusion
This study provides compelling evidence in support of the clinical rationale for the WHO 2021 reclassification. Despite a favorable prognosis, aggressive multimodal therapy was strongly associated with improved survival, though potential indication bias necessitates cautious interpretation and prospective validation. The developed ML model serves as a robust tool for personalized risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Neurosurgery, Liangping People's Hospital of Chongqing, Chongqing, China.
Förderung
- Bureau of Science and Technology Nanchong City
- North Sichuan Medical College
- Affiliated Hospital of North Sichuan Medical College
- Health China BuChang ZhiYuan Public welfare projects for Heart and brain health of Zhongshe Social Work Development Foundation
- Sichuan Medical Science and Technology Innovation Research Association
Zitieren
APA
Du, D., Jike, A., Yu, D., Tan, S., Wang, S., & Li, S. (2026). Real‐World Validation of the Clinical Distinctiveness of IDH‐Mutant Glioblastoma in the SEER Transition Era: A Population‐Based Study Integrating Machine Learning. Brain and Behavior. https://doi.org/10.1002/brb3.71641
Vancouver
Du D, Jike A, Yu D, Tan S, Wang S, Li S. Real‐World Validation of the Clinical Distinctiveness of IDH‐Mutant Glioblastoma in the SEER Transition Era: A Population‐Based Study Integrating Machine Learning. Brain and Behavior. 2026. doi:10.1002/brb3.71641
BibTeX
@article{Du2026,
author = {Du, Dewei and Jike, Amu and Yu, Dongnan and Tan, Shizheng and Wang, Shuming and Li, Shun},
title = {Real‐World Validation of the Clinical Distinctiveness of IDH‐Mutant Glioblastoma in the SEER Transition Era: A Population‐Based Study Integrating Machine Learning},
journal = {Brain and Behavior},
year = {2026},
doi = {10.1002/brb3.71641}
}
EUVIMED